Abolis develops high-impact innovations and provides tailor-made industrial solutions based on micro-organisms for various industries including food, healthcare, cosmetics, and chemistry.

Abolis Biotechnology

Abolis Biotechnologies | 7,616 followers on LinkedIn. Decipher - Innovate - Build | Abolis is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to build a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms.
Founded in 2014, Abolis is made up of a team of over 54 people, sharing a scientific and humanist ambition.

VP Transformation & Operations Management | Business Value & Customer Centric Driven | Digital & Cloud Transformation Journey Advisor | Biotech

Frédéric Austruy

Damien Bourel

Fermentation Department Manager at Abolis Biotechnologies

Jean-Michel Bavouzet

Managing Partner at Figem

Dominique Megret

Abolis Biotechnologies

Réindustrialiser et décarboner l'industrie, deux objectifs atteignables grâce aux biotechnologies. Bpifrance La French Fab France Industrie

Thanks to Fiona Mischel and SynBioBeta for the article. Abolis will continue to develop its business in Cosmetics, Pharma, Food ingredients and chemicals.

Merci à Françoise de Vaugelas et Formule Verte pour cet échange. Les défis existent pour industrialiser les biotechnologies. Il y a déjà de beaux succès et de belles opportunités à venir, même si les développements ne sont pas de longs fleuves tranquilles. Gwenael Servant, PhD Microbiome Studio

Why microbes and biotechnologies are essential to our economy ? Because you can address the main challenges we are facing: health, food production, energy, materials. Take the time to read this very interesting paper: https://lnkd.in/e7Dr-H6N "Microorganisms, including bacteria, archaea, viruses, fungi, and protists, are essential to life on Earth and the functioning of the biosphere. Here, we discuss the key roles of microorganisms in achieving the United Nations Sustainable Development Goals (SDGs), highlighting recent and emerging advances in microbial research and technology that can facilitate our transition toward a sustainable future." Abolis Biotechnologies Microbiome Studio SICOS (chimie fine & biotech) Douglas Robinson

Gwenael Servant, PhD

Most of the people do not expect to be surrounded by chemistry, it's part of our everyday (comfortable) life. Many of those chemicals can be made using alternative processes. This is what we do @ Abolis Biotechnologies , we use biotechnology as a way to produce molecules, not from oil, but from non fossil feedstock, so that we can limit GHG emissions and carbon footprint of chemicals. Biotechnology is also an incredible tool to innovate (new molecules) or to reshore manufacturing. Contact us so that we can talk about it !

Want to know more about Abolis ? Check this video..... Abolis Biotechnologies Microbiome Studio

Cyrille PAUTHENIER était présent ce matin sur le plateau de BFM Business avec Laure Closier pour présenter ce qu'apportent les biotechnologies et la contribution d'Abolis à la décarbonation et la "défossilisation" de l'économie. Abolis Biotechnologies Microbiome Studio

We're thrilled to be announcing that we've secured funding from new investors to fuel our growth trajectory. BOLD Evonik Venture Capital DTCF | DeepTech & Climate Fonds Clay Capital fka VisVires New Protein Icos Capital LIBERSET

Metric
Company Name	Abolis Biotechnology
Symbol
MSH ID	FR:ABOLIS
Market	PRIVATE
Sector	Technology
Industry	Biotechnology
Country	FR
Stage
Employee Count
Website	abolis.fr
LinkedIn	abolis-biotechnologies
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ABOL

FR:ABOLIS

Abolis Biotechnology

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue